128 related articles for article (PubMed ID: 37558640)
21. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
[TBL] [Abstract][Full Text] [Related]
22. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
23. Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
Saeter T; Vlatkovic L; Waaler G; Servoll E; Nesland JM; Axcrona K; Axcrona U
Prostate; 2017 Jun; 77(8):859-865. PubMed ID: 28240424
[TBL] [Abstract][Full Text] [Related]
24. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings.
Robinson BD; Epstein JI
J Urol; 2010 Oct; 184(4):1328-33. PubMed ID: 20723921
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens.
Kimura K; Tsuzuki T; Kato M; Saito AM; Sassa N; Ishida R; Hirabayashi H; Yoshino Y; Hattori R; Gotoh M
Prostate; 2014 May; 74(6):680-7. PubMed ID: 24481730
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.
Fujiwara M; Akamatsu S; Sumiyoshi T; Segawa T; Mizuno K; Yoshino T; Goto T; Sawada A; Saito R; Kobayashi T; Yamasaki T; Inoue T; Ogawa O
Clin Genitourin Cancer; 2019 Oct; 17(5):e923-e929. PubMed ID: 31307917
[TBL] [Abstract][Full Text] [Related]
28. Concomitant intraductal carcinoma of the prostate and response to hormonal therapy in metastatic prostate carcinoma.
Abascal-Junquera JM; Fumadó-Ciutat L; Gasa-Galmes B; Costa-Planells M; Munarriz-Polo M; Sanromà-Salvà A; Polaina-Barroso L; Solà-Marqués C; Juanpere-Rodero N; Lloreta-Trull J; Cecchini-Rosell L
Actas Urol Esp (Engl Ed); 2021; 45(6):455-460. PubMed ID: 34147428
[TBL] [Abstract][Full Text] [Related]
29. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
30. A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
Iwasawa T; Kosaka T; Morita S; Mikami S; Nakamura K; Hongo H; Nishihara H; Oya M
BMC Med Genomics; 2022 Jun; 15(1):138. PubMed ID: 35725469
[TBL] [Abstract][Full Text] [Related]
31. [A Case of Primary Central Nervous System Lymphoma that Developed during the Treatment of Castration-Resistant Prostate Cancer].
Yumiba S; Nakayama M; Kuribayashi S; Tsuji H; Hatano K; Nakai Y; Kakimoto KI; Nishimura K
Hinyokika Kiyo; 2020 Feb; 66(2):49-52. PubMed ID: 32160733
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
33. Intraductal Carcinoma of the Prostate without High-Grade Invasive Adenocarcinoma: Report of Two Cases and Review of the Literature.
Ortiz-Rey JA; Bellas-Pereira A; San Miguel-Fraile P; Morellón-Baquera R; Domínguez-Arístegui P; González-Carreró Fojón J
Arch Esp Urol; 2022 Nov; 75(9):738-745. PubMed ID: 36472055
[TBL] [Abstract][Full Text] [Related]
34. Intraductal carcinoma of the prostate.
Robinson B; Magi-Galluzzi C; Zhou M
Arch Pathol Lab Med; 2012 Apr; 136(4):418-25. PubMed ID: 22458904
[TBL] [Abstract][Full Text] [Related]
35. Presence of corpora amylacea among prostate cancer cells: an unrecognised feature of intraductal carcinoma of the prostate.
Sugie M; Takahara T; Ohashi A; Sassa N; Tsuzuki T
Pathology; 2021 Aug; 53(5):574-578. PubMed ID: 34154844
[TBL] [Abstract][Full Text] [Related]
36. Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression.
Dawkins HJ; Sellner LN; Turbett GR; Thompson CA; Redmond SL; McNeal JE; Cohen RJ
Prostate; 2000 Sep; 44(4):265-70. PubMed ID: 10951489
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer.
Panchal S; Shachar O; O'Malley F; Crystal P; Escallon J; Crook J; Bane A; Bordeleau L
Nat Rev Clin Oncol; 2009 Oct; 6(10):604-7. PubMed ID: 19787003
[TBL] [Abstract][Full Text] [Related]
38. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
[TBL] [Abstract][Full Text] [Related]
39. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
